Evidence map›Paper›PMID 28814316›Full record

ArticleParasites & vectors2017

Evaluation of sarolaner and spinosad oral treatments to eliminate fleas, reduce dermatologic lesions and minimize pruritus in naturally infested dogs in west Central Florida, USA.

Michael W Dryden, Michael S Canfield, Emily Niedfeldt, Amanda Kinnon, Kimberly Kalosy, Amber Smith, Kaitlin M Foley, Vicki Smith, Todd S Bress, Nicole Smith and 2 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael W DrydenDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA. Dryden@vet.k-state.edu.
Michael S CanfieldAnimal Dermatology South, 7741 Congress Str, New Port Richey, FL, 34653, USA.
Emily NiedfeldtDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Amanda KinnonDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Kimberly KalosyDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Amber SmithDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Kaitlin M FoleyDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Vicki SmithDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Todd S BressAnimal Dermatology South, 7741 Congress Str, New Port Richey, FL, 34653, USA.
Nicole SmithAnimal Dermatology South, 7741 Congress Str, New Port Richey, FL, 34653, USA.
Mike EndrizziZoetis US LLC, 100 Campus Drive, W4668, Florham Park, NJ, 07932, USA.
Joyce LoginGBBM Consulting, 16036 Eagle River Way, Tampa, FL, 33624, USA.
Kansas State University · USZoetis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn in-home investigation of naturally flea infested dogs was conducted in West Central Florida, USA to evaluate and compare the effectiveness of two different oral flea adulticides to control flea infestations, minimize dermatologic lesions and reduce pruritus over an 8-week period.

methodsTwenty-nine dogs living in 19 homes and another 26 dogs residing in 16 different homes were orally administered either a sarolaner or spinosad chewable, respectively on day 0 and once between days 28-30. Products were administered by study personnel according to label directions. Flea populations on dogs were estimated using visual area counts and flea infestations in the indoor premises were assessed using intermittent-light flea traps on days 0, 7, 14, 21 and once between days 28-30, 40-45, and 56-60. Assessments of dermatologic lesions were conducted monthly during the study and severity of pruritus was evaluated throughout the study on the same schedule as flea counts were conducted. Concurrent treatments for existing skin disease were not allowed.

resultsThe administration of sarolaner or spinosad reduced flea populations on dogs by 99.0% and 97.3%, respectively within 7 days. Flea infestations on the sarolaner- and spinosad-treated dogs were reduced by > 99% at every counting period from day 14 post-treatment through the end of the 8-week study. At the end of the study 96.4 and 92.0% of the dogs treated with sarolaner and spinosad, respectively were flea-free. Flea populations in the indoor premises were also markedly reduced the end of the study, with 100 and 99.8% reductions in flea trap counts in the sarolaner and spinosad treatment groups, respectively. FAD lesion scores, atopic dermatitis lesions scores (CADESI-4) and pruritus severity scores were also markedly improved with both formulations.

conclusionsAn in-home clinical field study conducted during the summer of 2016 in subtropical Florida demonstrated that two-monthly administrations of either sarolaner or spinosad chewables almost completely eliminated flea infestations on dogs and in private residences, while markedly reducing dermatology lesions and pruritus.

Indexed as

Administration, OralAnimalsAzetidinesDog DiseasesDogsDrug CombinationsFlea InfestationsFloridaInsecticidesMacrolidesPruritusSiphonapteraSkinSpiro CompoundsAzetidinesDrug CombinationsInsecticidesMacrolidessarolanerspinosadSpiro CompoundsAtopic dermatitisCat fleaCtenocephalides felis felisDogsField studyFleaFlea allergy dermatitisFlea bite dermatitisFlea controlPruritusSarolanerSpinosad

Identifiers

PMID28814316
PMCPMC5559866
OpenAlexW2746485087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.